Evidence map›Paper›PMID 39811141›Full record

ArticleACS medicinal chemistry letters2025

Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E Activity in Cancer.

Emilio L Cárdenas, Rachel L O'Rourke, Arya Menon, Gabriela Vega-Hernández, Jennifer Meagher, Jeanne Stuckey, Amanda L Garner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. CRISPR RiPCA for Investigating eIF4E-mACS chemical biology · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Emilio L CárdenasDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Rachel L O'RourkeDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Arya MenonDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Gabriela Vega-HernándezProgram in Chemical Biology, University of Michigan, Ann Arbor, Michigan 48109, United States.
Jennifer MeagherLife Science Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.
Jeanne StuckeyLife Science Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.
Amanda L GarnerDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID https://orcid.org/0000-0002-0870-3347

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Delineating the Biology of Translational Repressor 4E-BP1R01GM132342 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GARNER, AMANDA · 2020 to 2023
$1.4M
NCI NIH HHS P30 CA046592NIGMS NIH HHS R01 GM132342
6 · The paper itself

Abstract

Dysregulation of translation is a hallmark of cancer that enables rapid changes in cellular protein production to shape oncogenic phenotypes. Translation initiation is governed by the m

Identifiers

PMID39811141
PMCPMC11726381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.